Acrivon Therapeutics, Inc.
ACRV
$2.05
-$0.06-2.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.86% | -11.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.20% | -1.06% | |||
| Operating Income | 6.20% | 1.06% | |||
| Income Before Tax | 5.66% | -0.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.66% | -0.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.66% | -0.30% | |||
| EBIT | 6.20% | 1.06% | |||
| EBITDA | 6.43% | 1.19% | |||
| EPS Basic | 12.69% | -0.12% | |||
| Normalized Basic EPS | 12.69% | 2.13% | |||
| EPS Diluted | 12.69% | -0.12% | |||
| Normalized Diluted EPS | 12.69% | 2.13% | |||
| Average Basic Shares Outstanding | 8.05% | 0.17% | |||
| Average Diluted Shares Outstanding | 8.05% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||